Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)

Q: What does CUSIP 28036F105 represent in this 13F holders report?

CUSIP 28036F105 is the security identifier for EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q2 2024?

138 institutional investors reported EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q2 2024. Use the holders table for investor-level position and value details.

CUSIP: 28036F105

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 109,183,673
Total 13F shares: 101,617,706
Share change: +9,950,302
Total reported value: $1,830,101,707
Put/Call ratio: 12%
Price per share: $18.01
Number of holders: 138
Value change: +$179,027,088
Number of buys: 88
Number of sells: 50

Quarterly Holders Quick Answers

What is CUSIP 28036F105?
CUSIP 28036F105 identifies EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2024
Previous quarter: Q1 2024

Recent filing periods for CUSIP 28036F105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F	Company	14%	15,021,721	$273,996,191	—	31 Mar 2024	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	8.2%	8,909,091	$162,501,820	—	31 Mar 2024	13F
FMR LLC	13F	Company	5.8%	6,365,724	$116,110,807	—	31 Mar 2024	13F
BAKER BROS. ADVISORS LP	13F	Company	5.3%	5,840,059	$106,522,676	—	31 Mar 2024	13F
Novo Holdings A/S	3/4/5	10%+ Owner	— class O/S missing	6,071,703	$95,781,722	—	14 Sep 2022	3/4/5
BlackRock Finance, Inc.	13F	Company	4.7%	5,167,006	$94,246,190	—	31 Mar 2024	13F
VANGUARD GROUP INC	13F	Company	3.7%	4,017,433	$73,277,978	—	31 Mar 2024	13F
VIKING GLOBAL INVESTORS LP	13F	Company	3.1%	3,339,146	$60,906,023	—	31 Mar 2024	13F
Frazier Life Sciences Management, L.P.	13F	Company	3%	3,303,567	$60,257,062	—	31 Mar 2024	13F
Cormorant Asset Management, LP	13F	Company	2.8%	3,006,534	$54,839,180	—	31 Mar 2024	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	2.6%	2,874,586	$52,432,449	—	31 Mar 2024	13F
CITADEL ADVISORS LLC	13F	Company	2.5%	2,719,291	$49,599,868	—	31 Mar 2024	13F
Paradigm Biocapital Advisors LP	13F	Company	2.2%	2,446,373	$44,621,844	—	31 Mar 2024	13F
PERCEPTIVE ADVISORS LLC	13F	Company	2.1%	2,319,646	$42,310,343	—	31 Mar 2024	13F
TCG Crossover Management, LLC	13F	Company	2.1%	2,272,728	$41,454,559	—	31 Mar 2024	13F
VR Adviser, LLC	13F	Company	1.7%	1,818,182	$33,163,640	—	31 Mar 2024	13F
JANUS HENDERSON GROUP PLC	13F	Company	1.7%	1,805,312	$32,897,580	—	31 Mar 2024	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.6%	1,747,844	$31,880,674	—	31 Mar 2024	13F
New Leaf Venture Partners, L.L.C.	13F	Company	1.4%	1,553,661	$28,338,777	—	31 Mar 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.3%	1,369,897	$24,991,047	—	31 Mar 2024	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	1.2%	1,267,819	$23,125,019	—	31 Mar 2024	13F
EcoR1 Capital, LLC	13F	Company	1.1%	1,250,385	$22,807,022	—	31 Mar 2024	13F
STATE STREET CORP	13F	Company	1.1%	1,211,476	$22,097,322	—	31 Mar 2024	13F
Artal Group S.A.	13F	Company	0.74%	811,718	$14,805,736	—	31 Mar 2024	13F
Opaleye Management Inc.	13F	Company	0.61%	665,000	$12,129,600	—	31 Mar 2024	13F
Parkman Healthcare Partners LLC	13F	Company	0.6%	653,653	$11,922,631	—	31 Mar 2024	13F
Granahan Investment Management, LLC	13F	Company	0.56%	608,012	$11,090,139	—	31 Mar 2024	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.51%	559,334	$10,202,252	—	31 Mar 2024	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.49%	532,255	$9,708,331	—	31 Mar 2024	13F
NORTHERN TRUST CORP	13F	Company	0.46%	499,520	$9,111,245	—	31 Mar 2024	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.46%	497,162	$9,068,235	—	31 Mar 2024	13F
D. E. Shaw & Co., Inc.	13F	Company	0.43%	473,680	$8,639,923	—	31 Mar 2024	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.43%	472,903	$8,625,751	—	31 Mar 2024	13F
MPM BioImpact LLC	13F	Company	0.4%	441,259	$8,048,564	—	31 Mar 2024	13F
Woodline Partners LP	13F	Company	0.37%	405,132	$7,389,608	—	31 Mar 2024	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.36%	392,735	$7,163,486	—	31 Mar 2024	13F
MORGAN STANLEY	13F	Company	0.34%	374,718	$6,834,856	—	31 Mar 2024	13F
Nuveen Asset Management, LLC	13F	Company	0.31%	338,004	$6,165,193	—	31 Mar 2024	13F
S.c.a. Candriam	13F	Individual	0.3%	329,000	$6,000,960	—	31 Mar 2024	13F
DAFNA Capital Management LLC	13F	Company	0.28%	306,197	$5,585,033	—	31 Mar 2024	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.27%	299,288	$5,459,013	—	31 Mar 2024	13F
KENNEDY CAPITAL MANAGEMENT LLC	13F	Company	0.27%	293,265	$5,349,154	—	31 Mar 2024	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.26%	284,600	$5,191,104	—	31 Mar 2024	13F
Bank of New York Mellon Corp	13F	Company	0.19%	212,265	$3,871,714	—	31 Mar 2024	13F
ADAR1 Capital Management, LLC	13F	Company	0.17%	180,911	$3,299,817	—	31 Mar 2024	13F
VOLORIDGE INVESTMENT MANAGEMENT, LLC	13F	Company	0.16%	175,901	$3,208,434	—	31 Mar 2024	13F
Trexquant Investment LP	13F	Company	0.12%	126,332	$2,304,296	—	31 Mar 2024	13F
Cubist Systematic Strategies, LLC	13F	Company	0.09%	103,208	$1,882,514	—	31 Mar 2024	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.08%	92,400	$1,685,376	—	31 Mar 2024	13F
BARCLAYS PLC	13F	Company	0.08%	87,244	$1,591,331	—	31 Mar 2024	13F

Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) as of Q2 2024

As of 30 Jun 2024, Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) was held by 138 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 101,617,706 shares. The largest 10 holders included ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BlackRock Inc., BAKER BROS. ADVISORS LP, FMR LLC, VANGUARD GROUP INC, Frazier Life Sciences Management, L.P., Cormorant Asset Management, LP, and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C). This page lists 138 institutional shareholders reporting positions in this security for the Q2 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders

126

Q2 2024 holders

138

Holder diff

Investor	Q1 2024 Shares	Q2 2024 Shares	Share Diff	Share Chg %	Q1 2024 Value $	Q2 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.